# Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

> **NCT01218568** · NA · COMPLETED · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 120 (actual)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** Rifaximin plus lactulose
- **DRUG:** Lactulose

## Key facts

- **NCT ID:** NCT01218568
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2013-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218568, "Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01218568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*